Search PubMed⌕ Search

Biomedical subjects

M Krasnowska

Publications and source records attributed to M Krasnowska.

At least 37 records · Page 2Linked to original sources
PubMed1994

[Bronchial hyperreactivity in patients with bronchial asthma treated with salbutamol and salbutamol combined with beclocort or nedocromil].

Salbutamol alone (400 micrograms per day) or salbutamol together with beclocort (1 mg per day) was used in 20 patients with mild asthma. 12 patients received during a month salbutamol combined with nedocromil (Tilade 8 mg per day). Prior starting treatment and after concluding a histamine provocation challenge was performed allowing to assess the bronchodilating properties of salbutamol. We conclude that: salbutamol alone produced a statistically nonsignificant increase of bronchial hyperactivity; a combination of salbutamol with beclocort or nedocromil did not increase the bronchial hyperactivity; during the three month trial with salbutamol alone or in a combination with a antiinflammatory agent the bronchodilatatory effect of salbutamol remained the same.

Adult↗
PubMed1994

[Effect of vaporizing high doses of ipratropium bromide on lung ventilation in patients with chronic obstructive pulmonary disease and bronchial asthma].

Authors compared efficacy of high Atrovent doses and Salbutamol on pulmonary ventilation. Examinations were performed in 20 patients with BA and 20 patients with COPD. Each drug was given on separate days in increasing doses (0.04; 0.25 and 0.5 mg) of Atrovent and 0.2 mg of Salbutamol. Bronchodilatation was assessed by measurement of FEV1; FEF25%, FEF50%, FEF75%. Maximal effect in patients with COPD was reached with doses of 0.25 and 0.5 mg of Atrovent (delta FEV1(%) +22). Salbutamol and 0.04 mg of Atrovent were significantly less effective. In patients with BA Salbutamol (delta FEV1(%) +49) are likely to be more effective bronchodilator an Atrovent (delta FEV1(%) +26).

Albuterol↗
PubMed1993

[Bronchial hyperreactivity after chronic use of salbutamol].

15 patients with bronchial asthma received inhalations of salbutamol three times daily (200 mcg) for 2 months. Spirometry was carried out at the beginning of the study, one and two months after starting the study. The bronchodilating effect and non-specific bronchial hyperreactivity assessed with the histamine bronchoprovocation test were studied. Two month treatment with salbutamol decreased the bronchodilating effect and at the same time produced an increase of non-specific bronchial hyperreactivity.

Adult↗
PubMed1993

[Bronchodilating action of salbutamol depending on route of administration].

The aim of this study was to demonstrate the differences in salbutamol's bronchodilating effect related to administration routes of the drug. Three different administration routes were assessed: salbutamol given by a MDI device, a nebulizer and intravenously. The following increases of FEV1 were seen after administration routes: MDI--12%, nebuliser--27%, intravenously--22%. These differences were statistically significant.

Administration, Inhalation↗
PubMed1992

[Effect of long term systemic steroid therapy on the cardiac muscle].

In asthmatic patients treated on a long term basis with steroids echocardiographic examination of the heart disclosed morphological and functional changes in the heart muscle. Such changes were not found in asthmatic treated occasionally with steroids. Differences between both groups depended on decreased contractibility of the heart muscle and concentric hypertrophy of the left ventricle present in asthmatic treated on a long term basis with systemic steroids.

Adrenal Cortex Hormones↗
PubMed1992

Inhaled natural human interferon alpha induces bronchospastic reactions in asthmatics.

There is a relationship between viral infection and aggravation of bronchial asthma symptoms. Viruses belong to the strongest and fast acting inducers of interferon (IFN), which, in turn, may enhance histamine release from effector cells. We have administered IFN intrabronchially to 49 patients suffering from bronchial asthma. The impairment of lung ventilation with significant decrease of forced expiratory volume in one second (FEV1) have been observed in majority of the patients who inhaled crude or purified IFN preparations.

Administration, Inhalation↗
PubMed1992

[Interferon as a bronchospastic factor in patients with bronchial asthma].

Twenty three asthmatics were examined during the symptoms free period. Each subject inhaled aerolised human interferon alpha (Hu IFN-alpha, Le) in increasing doses 4000 and 8000 units. IFN inhalation provoked significant decline in FEV1 (by 9.9% after the 1st dose and 6.6% after the 2nd dose on average). This results indicate that inhaled interferon induces bronchospastic reactions in asthmatics.

Adolescent↗
PubMed1990

[Acute myocardial infarction as a consequence of anaphylactic reaction after administration of urovision].

The case of 52-year old patient was presented who developed urticaria and strong anginal pain after intravenous administration of uropoline. On the basis of typical clinical picture, electrocardiographical and biochemical changes acute myocardial infarction was recognised. It is thought to have developed as the consequence of anaphylactic reaction following intravenous administration of x-rays contrast substance.

Anaphylaxis↗